|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4364934A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
DE3788914T2
(de)
|
1986-09-08 |
1994-08-25 |
Ajinomoto Kk |
Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
ATE151467T1
(de)
|
1987-11-30 |
1997-04-15 |
Univ Iowa Res Found |
Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
|
|
WO1989009221A1
(en)
|
1988-03-25 |
1989-10-05 |
University Of Virginia Alumni Patents Foundation |
Oligonucleotide n-alkylphosphoramidates
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
JPH06504628A
(ja)
|
1990-12-20 |
1994-05-26 |
エクソン・ケミカル・パテンツ・インク |
リソグラフィー及び腐食防止コーティング用途向けのｕｖ／ｅｂ硬化性ブチルコポリマー
|
|
EP0575485A1
(en)
|
1991-03-01 |
1993-12-29 |
Dyax Corp. |
Process for the development of binding mini-proteins
|
|
DK0580737T3
(da)
|
1991-04-10 |
2004-11-01 |
Scripps Research Inst |
Heterodimere receptorbiblioteker ved anvendelse af phagemider
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
EP0733059B1
(en)
|
1993-12-09 |
2000-09-13 |
Thomas Jefferson University |
Compounds and methods for site-directed mutations in eukaryotic cells
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CZ296576B6
(cs)
|
1999-02-12 |
2006-04-12 |
Sankyo Company Limited |
Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
PT1592793E
(pt)
|
2003-02-10 |
2009-09-30 |
Santaris Pharma As |
Compostos oligoméricos para a modulação da expressão de survivina
|
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
GB0324854D0
(en)
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
EP1984499B1
(en)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
６−修飾された二環式核酸類似体
|
|
EP2023940B1
(en)
|
2006-05-05 |
2011-06-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
ES2603379T3
(es)
|
2006-10-09 |
2017-02-27 |
Roche Innovation Center Copenhagen A/S |
Compuestos antagonistas de ARN para la modulación de PCSK9
|
|
WO2008049085A1
(en)
|
2006-10-18 |
2008-04-24 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
WO2008113832A2
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
DK2563753T6
(en)
|
2010-04-27 |
2016-04-04 |
Synaffix Bv |
Fused cyclooctynforbindelser and their use in metal-free click-reactions
|
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
AR084020A1
(es)
|
2010-11-30 |
2013-04-17 |
Genentech Inc |
Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
|
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
|
KR102240217B1
(ko)
|
2012-09-25 |
2021-04-14 |
젠자임 코포레이션 |
근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
|
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
FI2911699T4
(fi)
|
2012-10-23 |
2025-12-09 |
Synaffix Bv |
Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
|
|
ES2817050T3
(es)
|
2013-02-04 |
2021-04-06 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido selectivos y usos de los mismos
|
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US9994641B2
(en)
|
2013-12-25 |
2018-06-12 |
Jcr Pharmaceuticals Co., Ltd. |
Anti-human transferrin receptor antibody that passes through blood-brain barrier
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
JP7506601B2
(ja)
*
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
IL321905A
(en)
*
|
2018-08-02 |
2025-09-01 |
Dyne Therapeutics Inc |
Muscle-targeted conjugates and their uses in the treatment of myotonia dystrophica
|
|
JP7576542B2
(ja)
*
|
2018-08-02 |
2024-10-31 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびそれらの使用
|
|
CN119874910A
(zh)
*
|
2019-06-07 |
2025-04-25 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
AU2021206234A1
(en)
*
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
AU2021318851A1
(en)
*
|
2020-07-23 |
2023-03-16 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|